Results 141 to 150 of about 354,322 (345)

Multiple Myeloma Presenting as Acute Tubulointerstitial Nephritis and Normal Serum Protein Electrophoresis [PDF]

, 2012
Multiple myeloma is uncommon in individuals younger than 40 years. Renal involvement is common in this disease, but acute tubulointerstitial nephritis is very rare. In 20% of patients, only the light chain is produced and serum protein electrophoresis is
Hajigholami, A., Momeni, A., Nasri, H.
core  

Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022

American Journal of Hematology, EarlyView.
Rong Wang, Amy J. Davidoff, Martin Schoen, John H. Huber, Eric J. Feuer, Jennifer Ruhl, Natalia Neparidze, Xiaomei Ma, Su‐Hsin Chang, Shi‐Yi Wang   +9 more
wiley   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, EarlyView.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up - a case report

Haematologica
Not available.
Sarah Decheiver, Anais Schavgoulidze, Sabrina Maheo, Pierre-Adrien Vion, Olivier Lucidarme, Jill Corre, Laurent Garderet   +6 more
doaj   +1 more source

Multiple myeloma [PDF]

Clinical Medicine, 2001
D, Samson, C, Singer
openaire   +2 more sources

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Dissecting immunophenotypic diversity in multiple myeloma via mass cytometry: a call for harmonized gating strategies

Frontiers in Immunology
Plasma cell disorders present challenges in phenotypic determination, as they range from monoclonality of plasma cells to multiple myeloma and plasma cell leukemia.
Mahmoud Singer, Milad Moloudizargari, Milad Moloudizargari, James Sanchez, Flavia Pichiorri, Flavia Pichiorri   +5 more
doaj   +1 more source

The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice [PDF]

, 2016
Zubin Zhang, Jiefei Tong, Xiaowen Tang, Jiaxiang Juan, Biyin Cao, Rose Hurren, Guodong Chen, Paul Taylor, Xin Xu, Chang-Xin Shi, Juan Du, Jian Hou, Guanghui Wang, Depei Wu, A. Keith Stewart, Aaron D. Schimmer, Michael F. Moran, Xinliang Mao   +17 more
openalex   +1 more source

Advances in Double‐Stranded DNA Targeting Technologies

Exploration, EarlyView.
Double‐stranded DNA (dsDNA) plays a crucial role in genetic information storage and disease management, but its inherent stability limits access to internal bases. To overcome this challenge, various high‐specificity molecular targeting technologies have been developed to destabilize the DNA structure.
Zuhao Shen, Yiqun Liu, Yingjie Hao, Yifan Bo, Xiaochuan Dai, Shihui Wang, Tian Xia, Xin Su, Huiyu Liu   +8 more
wiley   +1 more source

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

Blood Cancer Journal
The main objective of this multi-institutional study is to understand the effect of primary intravenous immunoglobulin (IVIG) replacement on clinical outcomes in recipients of BCMA-directed bispecific antibody (bsAb), where infection remains an important
Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anannya Patwari, Metodi Balev, Divaya Bhutani, Asis Shrestha, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Anup Trikannad, Sruthi Vellanki, Samer Al-Hadidi, Suzanne Lentzsch, Frits van Rhee, Aishee Bag, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi R. Shah, Carolina Schinke   +22 more
doaj   +1 more source